Abstract
Nano-sized drug delivery systems have emerged as a transformative approach in the treatment of chronic diseases, offering precision, enhanced bioavailability, and reduced systemic toxicity. These nanocarriers, including liposomes, dendrimers, polymeric nanoparticles, and solid lipid nanoparticles, provide controlled release and site-specific targeting, especially valuable in managing diseases such as cancer, diabetes, and cardiovascular disorders. This paper reviews the current advancements in nano-sized drug delivery systems, their mechanisms of action, material design, and clinical outcomes. We discuss how functionalized nanocarriers improve therapeutic indices, extend circulation time, and cross physiological barriers. Finally, the article explores regulatory hurdles and future directions for nanotherapeutics in chronic disease treatment.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Dr. Elena Kovalevskaya (Author)